Keywords: Partnering, Academia, Pharma and biotech, Venture capital funding, Burrill & Co, Bristol-Myers, Amylin, AstraZeneca, GlaxoSmithKline, Human Geniome Sciences, IPOs

Pharma partnering dollars continue to decline, Burrill & Co reports

Article | 06 August 2012

The recent $3.4 billion partnering agreement announced in July between US pharma company Bristol-Myers Squibb (NYSE: BNY) and Anglo-Swedish drug major ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

GlaxoSmithKline

Amylin

AstraZeneca

Bristol-Myers Squibb

Human Genome Sciences

Go to company listing